ArticleIranian journal of microbiology2025
Identification and antimicrobial susceptibility testing of
Article in Iranian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: As a Gram-positive bacterium, Materials and Methods: This study included 65 GBS strains collected from urine samples obtained from the Bouali Laboratory Complex, one of the largest laboratories in western Iran. VITEK 2 GP ID cards were used to identify all GBS isolates. VITEK 2 susceptibility testing for Gram-positive bacteria was performed according to the manufacturer's instructions using the AST-ST card. MIC method was performed after the detection of GBS strains. Results: We found that 53 (81.5%) of the GBS isolates showed resistance to tetracycline; 47 (72.3%), 40 (61.5%), and 30 (46.15%) of these had a resistance to erythromycin, clindamycin and ampicillin respectively. Conclusion: In the present study, the VITEK 2 system was validated as a user-friendly system that can serve as a rapid and accurate tool for identification and antimicrobial susceptibility testing of GBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.